Deciphering the β-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: Closer to clinical use?

Research output: Contribution to journalArticlepeer-review

Abstract

Human embryonic stem cells (hESCs) are a pluripotent cell type considered to have high potential for the treatment of cardiovascular disease by cell replacement therapies. Several groups have shown that hESCs can be differentiated in vitro into cardiac myocytes, which may be used to facilitate tissue regeneration by injection directly into damaged myocardium. However, several hurdles still need to be overcome before these cells can be used in clinical trials. In particular, because transplanted hESC-cardiac myocytes should integrate fully within the damaged heart, these cells must be functionally compatible with the host myocardium. To assess this aspect of hESC-cardiac myocytes, Brito-Martins et al. (2008) in this issue of the BJP, describe the responses of hESC-cardiac myocytes to β-adrenoceptor stimulation, compared to those of myocytes from adult human hearts. Data obtained using specific β-adrenoceptor agonists showed good compatibility of hESC-cardiac myocytes with adult human myocardium in terms of β-adrenoceptor response.

Original languageEnglish
Pages (from-to)625-626
Number of pages2
JournalBritish Journal of Pharmacology
Volume153
Issue number4
DOIs
Publication statusPublished - Feb 2008

Keywords

  • β-adrenoceptor
  • Cardiac myocyte
  • Embryonic stem cell
  • Human

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Deciphering the β-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: Closer to clinical use?'. Together they form a unique fingerprint.

Cite this